Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen, K Park… - The lancet …, 2012 - thelancet.com
Summary Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …
activity when tested in EGFR mutant models with mutations that confer resistance to EGFR …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen… - LANCET …, 2012 - scholarworks.bwise.kr
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen… - LANCET …, 2012 - nckur.lib.ncku.edu.tw
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen… - The Lancet …, 2012 - europepmc.org
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen, K Park… - Lancet …, 2012 - ntur.lib.ntu.edu.tw
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel… - The Lancet …, 2012 - researchoutput.ncku.edu.tw
Background: Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity
when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine …
when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen, K Park… - The Lancet …, 2012 - infona.pl
Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when tested in
EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel… - The Lancet …, 2012 - pubmed.ncbi.nlm.nih.gov
Background Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity when
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine-kinase …
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
VA Miller, V Hirsh, J Cadranel, YM Chen… - The Lancet …, 2012 - snucm.elsevierpure.com
Background: Afatinib, an irreversible ErbB-family blocker, has shown preclinical activity
when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine …
when tested in EGFR mutant models with mutations that confer resistance to EGFR tyrosine …
[引用][C] Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of …
V Miller, V Hirsh, J Cadranel, Y Chen… - THE LANCET …, 2012 - research.unipg.it
Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after
failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a …
failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a …